MedTrace Logo

Treatment of Refractory Diabetic Macular Edema With Infliximab

NCT00505947 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-02-20

No results posted yet for this study

Summary

The purpose of this study is to determine if treatment with infliximab improves macular edema which is refractory to laser photocoagulation in patients with diabetes.

Conditions

Interventions

DRUG

infliximab

infliximab 5 mg/Kg body weight by intravenous infusion

DRUG

placebo

placebo 5 mg/Kg body weight by intravenous infusion

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Petros Sfikakis, MD · University of Athens

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505947 on ClinicalTrials.gov